September 07, 2022 Press
Indivumed and CELLphenomics Announce Partnership
Indivumed GmbH and CELLphenomics GmbH today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.Indivumed and CELLphenomics Announce Partnership Read more
April 28, 2022 News
Indivumed Expands Its Certified Provider Portfolio
Today, we are happy to announce that Indivumed is now a “Certified Service Provider” of the Spatial Transcriptomics technology (Visium Spatial Gene Expression) by 10x Genomics not only for fresh frozen- but for FFPE tissue as well.Indivumed Expands Its Certified Provider Portfolio Read more
April 05, 2022 Press
Indivumed Celebrates 20th Anniversary
Indivumed GmbH today celebrated the company’s 20th anniversary milestone. Founded in Hamburg, Germany on April 5, 2002, Indivumed has rapidly expanded to become a leading innovator in the field of precision oncology.Indivumed Celebrates 20th Anniversary Read more
January 17, 2022 Press
Indivumed receives EU funding from ERDF structural fund
Indivumed receives EU funding from ERDF structural fundIndivumed receives EU funding from ERDF structural fund Read more
To meet all your needs in cancer research and drug development we offer you a broad spectrum of high-quality biospecimen samples including clinical data.
To further support your efforts in personalized oncology we offer you an holistic range of clinical, laboratory, and research services.
Indivumed’s long-standing expertise is ISO 9001:2015-certified and includes the collection, processing and storage of biological samples and clinical data from cancer patients; laboratory services and AI-advanced data analytics of multi-omics cancer data for biopharma service offerings as well as IP-generation and product development in the field of personalized oncology.
Discover more about Indivumed’s work and the future of personalized cancer medicine in the following lectures and videos.
The Challlenge and Importance of Standardizing Pre-Analytical Variables in Surgical Pathology Specimens for Clinical Care and Translational Research
Speaker: David Hicks, M.D.